Member Info for B2HS2L

Apologies, missed another link out: -

Also referenced within the article at the 'document' hotlink, gives access to a SAGE document:

21.05.2021 - Setting up medium-and long-term vaccine strain selection and immunity management for SARS-CoV-2
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988226/S1226_Setting_up_medium-_and_long-term_vaccine_strain_selection_and_immunity_management_for_SARS-CoV-2__1_.pdf

+++

30 pages :( but some of it essential reading for where Genomic Surveillance will go from here on.
Found pages 26/27 of interest.

COVID-19: Current coronavirus vaccines unlikely to protect against new variants in future, SAGE warns
The government's scientific advisers say COVID may continue to evolve for years to come and "eradication is extremely unlikely".

https://news.sky.com/story/amp/covid-19-current-coronavirus-vaccines-unlikely-to-protect-against-new-variants-in-future-sage-warns-12312976

Current COVID-19 vaccines are unlikely to protect against new variants of the virus in the future, the government's scientific advisers have warned.

In a paper published on Friday, the Scientific Advisory Group for Emergencies (SAGE) said coronavirus may continue to evolve for years to come and that "eradication is extremely unlikely".

The experts warn that eventually it is likely "current vaccines will fail to protect against transmission, infection, or even against disease caused by newer variants".

+++

Also referenced within the article:

Setting up medium- and long-term vaccine strain selection and immunity management for SARS-CoV-2:
Page 26/27
"COVID-19 Genomics UK Consortium (COG UK) and the UK Health Security Agency (UKHSA)

COG-UK undertakes genome sequencing and analysis, specifically looking for lineages and
variants of significance for experimental and epidemiological evaluation. COG-UK provides data
that influences public health interventions and policy decisions, through innovative partnerships
of NHS organisations, Public Health Agencies, lighthouse labs, and academic partners all
providing samples, sequencing and analysis capacity, together with the central sequencing hub
of the Wellcome Sanger Institute. It is likely that as the UK Health Security Agency becomes fully
functional much of the activity for routine GENOMIC SURVEILLANCE for public health will fall under its
remit. The UK Health Security Agency (UKHSA) is responsible for planning, preventing and
responding to external health threats, and providing intellectual, scientific and operational
leadership at national and local levels, as well as on the global stage. Through this, UKHSA
intends to ensure the nation can respond quickly and at greater scale to deal with pandemics
and future threats.

International SARS-CoV-2 genomics data resources

Pathogen genome sequencing is certain to continue to grow globally, not only for SARS-CoV-2
but also for a large range of other pathogens."

VanV -
Your "The DHSC issue is a pothole in the road".
I believe the rest of the sentence might read
"but is of small importance to the NCYT tracked vehicle becoming the worlds 'go-to' system for Genetic Sequencing ".

https://www.gov.uk/guidance/new-variant-assessment-programme?utm_medium=email&utm_campaign=govuk-notifications&utm_source=91cff3a8-66dc-4857-89d0-85be91dc181f&utm_content=immediately

"The NVAP support will be tailored to each individual country needs and includes:

Genomic sequencing in the UK.
Genomic sequencing support internationally to countries and hubs.
With regards to genomic sequencing in the UK, countries can send samples to the UK for genome sequencing and analysis. This can also include remote support from the UK for training, bioinformatics, risk assessment and public health decision-making and further biological assessment if required for impact on vaccines or treatments on variants.

With regards to genomic sequencing support internationally to countries and hubs, the NVAP offers support to increase genomic sequencing capacity and capability in-country.

Where there is potential scope for a country or an organisation to operate as a sequencing hub for the region, the NVAP support will help them scale up and develop as a larger hub. This support can include provision of additional consumables, reagents or equipment to increase throughput. It can also include remote training and mentoring for analytics, bioinformatics or risk assessment to support public health decision-making.

These hubs could support neighbouring countries and the global surveillance system. Hubs are being selected through joint work between the Foreign, Commonwealth and Development Office (FCDO), the Department of Health and Social Care (DHSC) and PHE, aligned with WHO assessment of global sequencing capacity.

Rapid support by a deployed team of experts may also be provided if needed."

Profits from this new income stream should be considerable.

Not a very balanced view:

1 However, could they now be obliged to repay money to the DHSC?
They would need to go on to discuss both possibilities in answer to this question, - they don't.

2 From 09.04 RNS "the Company has taken legal advice and believes it has strong grounds to assert its contractual rights," - subsequently installing Nick Plummer as General Counsel and Company Secretary at Novacyt Group.
ie A big hitter.

IMo management has said and done all it can to defend NCYT interests in relation to the contract.

https://www.expresstest.co.uk/heathrow-landing?utm_source=heathrowairport&utm_medium=crm&utm_campaign=heathrow_1

At the very bottom of this page you will see "Cignpost Diagnostics Limited trading as ExpressTest."

They are operating a drive through test facility from outside Heathrow at "N4 car park, Northern Perimeter Road, Heathrow Airport, Hounslow, Middlesex, TW6 2RL"

Collinson appear to have the monopoly inside Heathrow terminals, but I can't confirm this.

Anyone know if Cignpost / Express Test is using Genesig assays please?

Novacyt:
#GoldStandardGenomicSurveillanceSystem

Creates new Assays faster than the virus mutates..

GM's words in response to a question GKB47 sent to GM on behalf of many LSE NCYT BB posters last year:
""Novacyt has come (very quickly) from humble beginnings and as CEO I have tried to position the business in very difficult times to focus on delivery, not on hype. We continue to do this and we are building the foundations for a significant diagnostics business by ensuring we deliver performance, create expectations that can be realised and not to ramp the business. I know many companies that may have a different philosophy but in my experience hype without substance will always end up in misery."
++++
1 'tried to position the business in very difficult times to focus on delivery, not on hype'.
2 'create expectations that can be realised and not to ramp the business'.
3 'hype without substance will always end up in misery.'

So no - GM is not the same person as Porky

I hope GM has been waiting for official NVAP announcement before using social media and RNS for maximum impact.

Raided the back of the sofa last night, bought more after reading Kaeren's news.
Investment well beyond what I can afford to lose now haha!

Where there is potential scope for a country or an organisation to operate as a sequencing hub for the region, the NVAP support will help them scale up and develop as a larger hub. This support can include provision of additional consumables, reagents or equipment to increase throughput. It can also include remote training and mentoring for analytics, bioinformatics or risk assessment to support public health decision-making.

These hubs could support neighbouring countries and the global surveillance system. Hubs are being selected through joint work between the Foreign, Commonwealth and Development Office (FCDO), the Department of Health and Social Care (DHSC) and PHE, aligned with WHO assessment of global sequencing capacity.

"Rapid support by a deployed team of experts may also be provided if needed.

NVAP is committed to making data available globally through GIS-AID. This will allow it to inform UK risk assessment and pandemic control strategies globally."

++++

Is some of this from the overseas aid budget?

Kaeren, -
Great find indeed.
The New Variant Assessment Programme (NVAP) is an offer of UK capacity and expertise to detect and assess new variants of SARS-CoV-2 around the world.

From: Public Health England and UK Health Security Agency

GM has convinced these bodies that the Novacyt way of Genomic Sequencing is the way forward.
. Outside a laboratory
. With a company who can develop an assay to detect recently discovered VoC's.

Now we have their representation and positive recommendation abroad.

Well done GM

Make way for another international income stream.

Matt Hanc*ck on the 5 pm briefing seemed well pleased with UK genomic sequencing activities, going as far as to say they are sharing data concerning G.S. with other countries.

This will cement more 'bricks in the wall' in installing the Novacyt Genomic Surveillance SNPsig instruments and open platform assays, as the basis of future gold standard genomic surveillance portfolios.

NO G.S. COMPETITOR CAN TOUCH US FOR THE SPEED WITH WHICH WE DEVELOP THE NEW SNPsig ASSAYS, IN RESPONSE TO THE EMERGENCE OF NEW VoC VIRUS MUTATIONS.

:) :) :)

Wilson,
Thanks for this link:
https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests
The table within DOES NOT contain the following competitor products:

Perkin-Elmer NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit (equivalent to Variplex Assay, but with 7 hr processing cycle).

Roche cobas SARS-CoV-2 Variant Set 1 Test runs on the a high-volume cobas® 6800/8800 System. Unknown cycle time.

Thermo-Fisher TaqMan SARS-CoV-2 Mutation Panel - Variplex equivalent, 70 minute cycle time, Not offering B.1.617.? (India variant) detection yet.

Table does contain:
Novacyt SNP-sig Variplex - EUA 02.04.2021
From IFU:
Specimen test results are available to interpret in under three hours using the SNPsig®
VariPLEX™ (Covid-19). This time includes the time to PCR setup, PCR run time, and availability
of results.

+++

Will now be looking for any other competitors within this table!

From 23.04.2021 RNS
"Development of LFT to detect antigens for SARS-CoV-2, launch expected by end of Q2 2021
CE-IVD marked, for professional and home use LFT for the detection of SARS-CoV-2".

https://www.cnbc.com/video/2021/05/17/amazon-plans-to-launch-its-own-at-home-medical-testing-brand.html

IQ testing pre wedding ceremony.

Up to, but not including this post, I am serious.

Because I object to continually paying for more hospital care for numpties who are surprised they have the virus after a trip to a red or amber destination. I don't want to see any more NHS front line staff putting their health on the line, to nurse stupid people infected because of their own stupidity. Stupidity shouldn't be allowed to breed.

Why are we flying to these places. - A few flights now, with more later if Airlines see bums on seats.
Appalling way to squander hard won gains from lockdown. - Standby to import more viruses.

Mine too Wilson, - and I set it up!

By the way how is your chest chap.

Place pish here

Porky - I had a different understanding of reimbursement, - more in line with this:
https://www.justlanded.com/english/France/France-Guide/Health/Medical-costs